Table 6.
Efficacy of 400 mg sofosbuvir QD + ribavirin for 12 weeks.
| Cirrhosis | Prior treatment | SVR12 rate |
Study and trial phase | Ref. | |||
|---|---|---|---|---|---|---|---|
| GT-1 | GT-2 | GT-3 | GT-4 | ||||
| No cirrhosis |
Naïve | 84% (21/25) | 100% (4/4) | 100% (6/6) | Electron, phase 2a | Gane et al., 2013a | |
| Null response | 10% (1/10) | ||||||
| Naïve | 90.9% (10/11) | Phase 2 | Ruane et al., 2015 | ||||
| Experienced | 61.5% (8/13) | ||||||
| Experienced | 92.4% (85/92) | 67.9% (57/84) | POSITRON, phase 3 | Jacobson et al., 2013 | |||
| Experienced | 96.2% (25/26) | 36.8% (14/38) | FUSION, phase 3 | ||||
| Naïve | 98.3% (58/59) | 61.4% (89/145) | FISSION, phase 3 | Lawitz et al., 2013a | |||
| Naïve | 91.9% (159/173) | 75% (42/56) | HCV-TARGET, phase 4 | Feld et al., 2016a, Welzel et al., 2016a | |||
| Experienced | 87.5% (42/48) | 84.6% (22/26) | |||||
| Naïve | 97.6% (80/82) | Phase 3 | Omata et al., 2014 | ||||
| Experienced | 96.3% (52/54) | ||||||
| Naïve | 96.7% (29/30) | 0% (0/2) | VALENCE, phase 3 | Zeuzem et al., 2014a | |||
| Experienced | 93.8% (30/32) | 42.9% (3/7) | |||||
| Naïve | 86.4% (19/22) | Egyptian study | Doss et al., 2015 | ||||
| Experienced | 72.7% (16/22) | ||||||
| Naïve or experienced | 86.4% (19/22) | Real-world study | Maasoumy et al., 2016 | ||||
| Cirrhosis | Naïve | 33.3% (1/3) | Phase 2 | Ruane et al., 2015 | |||
| Experienced | 50% (2/4) | ||||||
| Naïve | 100% (2/2) | VALENCE, phase 3 | Zeuzem et al., 2014a | ||||
| Experienced | 77.8% (7/9) | 0% (0/2) | |||||
| Naïve | 76.6% (36/47) | VALOR, phase 4 | Ho et al., 2017 | ||||
| Experienced | 84.2% (16/19) | ||||||
| Experienced | 94.1% (16/17) | 21.4% (3/14) | POSITRON, phase 3 | Jacobson et al., 2013 | |||
| Experienced | 60% (6/10) | 19.2% (5/26) | FUSION, phase 3 | ||||
| Naïve | 71.9% (23/32) | 55.3% (21/38) | HCV-TARGET, phase 4 | Feld et al., 2016a, Welzel et al., 2016a | |||
| Experienced | 86.7% (26/30) | 37.9% (22/58) | |||||
| Naïve | 90.9% (10/11) | 34.2% (13/38) | FISSION, phase 3 | Lawitz et al., 2013a | |||
| Naïve | 100% (8/8) | Phase 3 | Omata et al., 2014 | ||||
| Experienced | 88.9% (8/9) | ||||||
| Naïve | 66.7% (2/3) | Egyptian study | Doss et al., 2015 | ||||
| Experienced | 60% (3/5) | ||||||
| Naïve or experienced | 90% (9/10) | Real-world study | Maasoumy et al., 2016 | ||||